Nanotropil novo tablets 100mg, 10pcs.

• Diseases of the central nervous system of various origins, especially those associated with metabolic disorders in the brain, intoxication (in particular, in post-traumatic conditions), accompanied by a deterioration in intellectual and mnestic functions, a decrease in motor activity;

• Neurotic conditions, manifested by lethargy, increased exhaustion, decreased psychomotor activity, impaired attention, memory impairment;

• Violations of the learning process;

• Psychoorganic syndromes, manifested by intellectual-mnestic disorders and apathetic-abulic phenomena, as well as sluggish states in schizophrenia;

• Convulsive states;

• Obesity (alimentary-constitutional genesis);

• Prevention of hypoxia, increasing resistance to stress, correction of the functional state of the body in extreme conditions of professional activity in order to prevent the development of fatigue and to increase mental and physical performance, correction of the daily biorhythm, inversion of the sleep-wake cycle;

• Chronic alcoholism (in order to reduce intellectual and mnestic disorders).

Pharmachologic effect
A nootropic drug with a pronounced antiamnestic effect has a direct activating effect on the integrative activity of the brain, promotes the consolidation of memory, improves concentration and mental activity, facilitates the learning process, increases the speed of information transfer between the cerebral hemispheres and the resistance of brain tissue to toxic effects, possesses anticonvulsant action and anxiolytic activity.

It has a positive effect on metabolic processes, stimulates redox processes, increases the energy potential of the body due to the utilization of glucose. Increases the content of norepinephrine, dopamine and serotonin in the brain, does not affect the level of GABA, does not bind to GABAA and GABAB receptors, and does not significantly affect the spontaneous bioelectrical activity of the brain.

It does not affect respiration and the cardiovascular system, exhibits an unexpressed diuretic effect, and has anorexigenic activity when used as a course.

The stimulating effect is manifested in the ability to provide a moderately pronounced effect, manifested in relation to motor reactions, increasing physical performance, as well as weakening the severity of the hypnotic effect of ethanol and hexobarbital.

The psychostimulating effect predominates in the ideational sphere.

The moderate psychostimulating effect of the drug is combined with anxiolytic activity. It has some analgesic effect, increasing the pain threshold.

The adaptogenic effect is manifested in an increase in the body’s resistance to stress under conditions of excessive mental and physical stress, with fatigue, hypokinesia and immobilization, at low temperatures.

While taking the drug, an improvement in vision was noted, which manifests itself in an increase in acuity, brightness and visual fields.

Improves blood flow to the lower extremities.

Stimulates the production of antibodies in response to the introduction of an antigen, which indicates immunostimulating properties, but at the same time does not contribute to the development of immediate hypersensitivity and does not change the allergic inflammatory reaction of the skin caused by the introduction of a foreign protein.

With course use, drug dependence, tolerance, “withdrawal syndrome” do not develop.

The effect is manifested in a single dose, which is important when using the drug in extreme conditions.
Absorption: Absorbed quickly. Absolute oral bioavailability is 100%.

Distribution: Penetrates into various organs and tissues, easily passes through the blood-brain barrier. The maximum concentration in the blood (Tmax) is reached after 1 hour.

Metabolism: Not metabolized in the body.

Excretion: The half-life (T1 / 2) is 3-5 hours. It is excreted unchanged: approximately 40% – by the kidneys and 60% – with bile and sweat.

Manufacturer

Obninsk HFC, Russia

Structure

1 tablet contains:

active substance: phonylpiracetam – 50.00 mg or 100.00 mg;

excipients: povidone K-17, microcrystalline cellulose, sodium carboxymethyl starch, magnesium stearate.

Clinical pharmacology

Individual intolerance;

Children under 18 years of age (safety and efficacy of the drug have not been established).

With caution

Patients with severe organic lesions of the liver and kidneys, severe arterial hypertension, severe atherosclerosis, previous panic attacks, acute psychotic conditions proceeding with psychomotor agitation – due to the possibility of exacerbation of anxiety, panic, hallucinations and delusions, as well as patients prone to to allergic reactions to nootropic drugs of the pyrrolidone group.

Application during pregnancy and during breastfeeding

Should not be prescribed during pregnancy and lactation due to the lack of data from clinical studies.

Application during pregnancy and lactation

Contraindications

Side effects

Interaction

How to take, course of administration and dosage

Overdose

Special instructions

Storage conditions

Shelf life

Active substance

Fonturacetam